Posts Tagged ‘Carlos López-Otín’

Wednesday July 22nd, 2015

Mutations in the dark side of the genome cause leukemia

A study, published today in the journal Nature, marks a milestone in the understanding of chronic lymphocytic leukemia, the most common leukemia in adults, as the genomes of normal and tumor cells for more than 500 patients have been sequenced providing novel mechanisms involved in the development of this tumor. Cancer originates due to the progressive accumulation of mutations in the genome of normal cells. This is why seven years ago the International Cancer Genome Consortium (ICGC) was established. The main aim of this consortium was to sequence the genome of tumor cells from at least 500 patients, and do it for each of the 50 most frequent types of cancer in the world. The Spanish-led consortium in charge of the chronic lymphocytic leukemia study has been the first team to accomplish this ambitious objective. In this work, led by Dr. Carlos Lopez-Otin, from the University of Oviedo and by Dr. Elias Campo, from Hospital Clinic, IDIBAPS and University of Barcelona, more than 60 researchers from different centers have collaborated to mine the three billion bases of each tumor genome in search of alterations responsible for the development of this disease.

Read the rest of this entry »

Comments Closed
Tuesday October 22nd, 2013

The genome of one of the most aggressive lymphomas has been sequenced

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas. The result of this work, published today in the prestigious U.S. journal Proceedings of the National Academy of Sciences (PNAS), presents the first comprehensive genomic analysis of this disease. “The study provides insight into causes and evolution of this complex neoplasm and has identified targets for new treatments“, says Dr. Silvia Beà, first author of the study.

Read the rest of this entry »

Comments Closed
Monday March 18th, 2013

Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia, co-led by Dr. Elías Campo, links for the first time cancer with errors in the protection of chromosomes

A research published by Nature Genetics explores a new mechanism that may contribute to the development of diverse tumors, including chronic lymphatic leukemia, a form of cancer that affects thousands of new patients each year in Spain. The researchers have detected for the first time in a human cancer the mutation of an essential gene for the protection of the telomeres, situated on the edges of the chromosomes. The research, directed by Carlos López-Otín, of the University Institute of Oncology of the University of Oviedo, Elías Campo, of the Clínic Hospital/University of Barcelona, and María Blasco, director of the National Center of Oncological Research (CNIO), breaks new ground for the Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday December 10th, 2012

Dr. Elías Campo comments for Nature Genetics two innovative works about the genomics of Burkitt lymphoma

Burkitt lymphoma is an aggressive B-cell neoplasm initially recognized by Dennis Burkitt, a prescient surgeon working in Uganda in the middle years of the last century. Two studies in the last issue of Nature Genetics identify the landscape of somatic mutations in Burkitt lymphoma and highlight the pathogenic and clinical relevance of inactivating mutations of ID3. Dr. Elías Campo, Research Director of the Hospital Clínic of Barcelona and Director of the Fundació Clínic, writes a news article in the same issue about this two works, in a section called News and Views. The IDIBAPS team he leads, Human and experimental functional oncomorphology, knows well about genetics of such diseases, as he is the co-director of the Chronic Lymphocytic Leukemia (CLL) Genome Project.

Read the rest of this entry »

Comments Closed
Monday October 15th, 2012

Spanish scientists decipher the first epigenomes of CLL

The study, published today in Nature Genetics, represents a new perspective on cancer research, integrating the results of the complete sequencing of the genome and epigenome of patients with leukemia. Researchers identify the cells that cause the disease, discovered new molecular mechanisms involved in its development and improve its diagnosis.

The research is part of the Chronic Lymphocytic Leukemia Genome Spanish Consortium, with the participation of researchers from the BLUEPRINT European Consortium for the study of the epigenome. During the past two years this consortium, which is part of the International Cancer Genome Consortium, has published two works in the journals Nature and Nature Genetics that allowed the characterization of the genetic map of mutations associated with the disease.

Read the rest of this entry »

Comments Closed